SPECIFIC PRODUCTS
VIOXX CLAIMS
VIOXX SIDE EFFECTS
Common Vioxx side effects can include:
-
Heart attack
Strokes
Chest pains
Palpitations
Irregular heartbeat
Fluid retention
Metabolic side effects
Respiratory problems
Digestive problems
Skin problems
Fever
Ears, nose and throat problems
Immune system deficiencies
Abdominal pain
Fatigue
Dizziness
Hypertension
Diarrhoea
Dyspepsia
Epigastric discomfort
Heartburn
Nausea
Sinusitis
Back pain
Headache
Bronchitis
Urinary tract infection
We are an independent network of specialist personal injury solicitors offering free legal advice on defective pharmaceutical products. All of our solicitors use the no win no fee scheme and do not ask for any financial contribution from you as the case proceeds. Our claims are completely risk free. For free advice on Vioxx side effects from a specialist law firm just complete the contact form and a member of The Law Society panel of personal injury experts will telephone you with no obligation.
This drug has an extremely chequered history with concerns being raised well before the drug was licensed for use. As far back as November 1996 a Merck official advised that there was a substantial chance that there would be significantly higher rates of cardiovascular problems for users of the drug. This Vioxx side effects warning was again outlined in an internal memo in February 1997 however notwithstanding these concerns on November 23, 1998, Merck submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration. The FDA approved its use on May 20, 1999 for the management of acute pain in adults and for relief of the signs and symptoms of osteoarthritis. On November 18, 1999, a meeting of the Data and Safety Monitoring Board (DSMB) raised concerns about the "excess deaths and cardiovascular adverse experiences". On March 17, 2000, Merck updated the product label by adding in the "adverse events" section of the label certain "cardiovascular" reports. The VIGOR study published in the November 2000 issue of the New England Journal of Medicine revealed a significant increase in the number of myocardial infarctions/heart attacks and strokes in patients using this Merck product. On May 22, 2001 Merck issued a press release entitled "Merck Confirms Favourable Cardiovascular Safety Profile of Vioxx", claiming Vioxx has a "… favourable cardiovascular safety profile". On August 22, 2001, a study published in Journal of the American Medical Association by Drs. Mukherjee, Nissen, and Topol indicated that Vioxx was linked to an increase in blood clots, heart attacks and strokes based on their review of previous clinical trials. Numerous other studies and research programs subsequently cast doubt on the products safety and the APPROVe study (Adenomatous Polyp Prevention Vioxx®) finally tipped the balance and on September 30, 2004 at 9:00am Eastern Standard Time, Merck & Co., Inc., the manufacturer, announced a voluntary withdrawal of the arthritis and pain relief drug from the worldwide drug market.
24/7 HELPLINE 0845 177 0700